Figure 8.
Frequency of second-line treatment (n = 270). B, bendamustine ± prednisone; BR, bendamustine + rituximab ± prednisone; F, fludarabine; FCR, fludarabine + cyclophosphamide + rituximab ± prednisone; others, regimens with frequency <5%
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.